doi: 10.1038/s41467-024-49655-6
In the past decades, several groups have found that drugs that harmine and other dual specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors are able to induce proliferation of human -cell and increase islet mass in vitro and vivo, and its pro-proliferative effects primarily operate via translocation of nuclear factor of activated T-cells (NFAT) transcription factors to the nucleus, with the consequent transactivation of cyclins such as cyclin A, CDKs such as CDK1, and repression of CDK-inhibitors such as p15 INK4 , p21 CIP1 , and p57 KIP2 [42, 43]
It doesnt work forever, and at some point, your body reestablishes its set point, and your weight loss stops or plateaus
Weight regain after stopping is real, documented in the STEP 4 trial, and expected when the biology of obesity isn't also addressed